| Year |
Citation |
Score |
| 2023 |
Liu Z, Liu W, Wang W, Ma Y, Wang Y, Drum DL, Cai J, Blevins H, Lee E, Shah S, Fisher PB, Wang X, Fang X, Guo C, Wang XY. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proceedings of the National Academy of Sciences of the United States of America. 120: e2302878120. PMID 37722058 DOI: 10.1073/pnas.2302878120 |
0.312 |
|
| 2022 |
Liu Y, Fang X, Li Y, Bing L, Li Y, Fang J, Xian X, Zhang W, Li J, Zhao Z, Zhu Y. Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. The Journal of Pharmacy and Pharmacology. PMID 35641094 DOI: 10.1093/jpp/rgac026 |
0.312 |
|
| 2020 |
Wang W, Wu J, Mukherjee A, He T, Wang XY, Ma Y, Fang X. Lysophosphatidic acid induces tumor necrosis factor-alpha to regulate a pro-inflammatory cytokine network in ovarian cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32851734 DOI: 10.1096/Fj.202001136R |
0.384 |
|
| 2020 |
Ma Y, Wang W, Devarakonda T, Zhou H, Wang XY, Salloum FN, Spiegel S, Fang X. Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation. Scientific Reports. 10: 1450. PMID 31996743 DOI: 10.1038/S41598-020-58334-7 |
0.397 |
|
| 2019 |
Guo C, Chen S, Liu W, Ma Y, Li J, Fisher PB, Fang X, Wang XY. Immunometabolism: A new target for improving cancer immunotherapy. Advances in Cancer Research. 143: 195-253. PMID 31202359 DOI: 10.1016/Bs.Acr.2019.03.004 |
0.342 |
|
| 2018 |
Ma Y, Wang W, Idowu MO, Oh U, Wang XY, Temkin SM, Fang X. Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876. Cancers. 11. PMID 30602670 DOI: 10.3390/Cancers11010033 |
0.429 |
|
| 2018 |
Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, Fang X. Fatty Acid Oxidation: An Emerging Facet of Metabolic Transformation in Cancer. Cancer Letters. PMID 30102953 DOI: 10.1016/J.Canlet.2018.08.006 |
0.389 |
|
| 2017 |
Ma Y, Min HK, Oh U, Hawkridge AM, Wang W, Mohsin AA, Chen Q, Sanyal A, Lesnefsky EJ, Fang X. The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals. The Journal of Biological Chemistry. PMID 29046352 DOI: 10.1074/Jbc.M117.812925 |
0.343 |
|
| 2017 |
Fang X, Hong Y, Dai L, Qian Y, Zhu C, Wu B, Li S. CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Molecular Carcinogenesis. PMID 28618089 DOI: 10.1002/mc.22691 |
0.377 |
|
| 2016 |
Li J, Yang Z, Chen Z, Bao Y, Zhang H, Fang X, Yang W. ATF3 suppresses ESCC via downregulation of ID1. Oncology Letters. 12: 1642-1648. PMID 27602100 DOI: 10.3892/ol.2016.4832 |
0.353 |
|
| 2016 |
Ma Y, Yu C, Mohamed EM, Shao H, Wang L, Sundaresan G, Zweit J, Idowu M, Fang X. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer. Oncogene. PMID 27132509 DOI: 10.1038/Onc.2016.150 |
0.395 |
|
| 2016 |
Kyte SL, Toma W, Damaj MI, Fang X, Gewirtz DA. Abstract 3574: Nicotine prevents chemotherapy-induced peripheral neuropathy in vivo, and fails to stimulate the growth of lung cancer cells or interfere with the effectiveness of chemotherapy in vitro Cancer Research. 76: 3574-3574. DOI: 10.1158/1538-7445.Am2016-3574 |
0.375 |
|
| 2015 |
Shao H, Mohamed EM, Xu GG, Waters M, Jing K, Ma Y, Zhang Y, Spiegel S, Idowu MO, Fang X. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. PMID 26716645 DOI: 10.18632/Oncotarget.6757 |
0.502 |
|
| 2015 |
Li W, Mukherjee A, Wu J, Zhang L, Teves ME, Li H, Nambiar S, Henderson SC, Horwitz AR, Strauss Iii JF, Fang X, Zhang Z. Sperm Associated Antigen 6 (SPAG6) Regulates Fibroblast Cell Growth, Morphology, Migration and Ciliogenesis. Scientific Reports. 5: 16506. PMID 26585507 DOI: 10.1038/Srep16506 |
0.324 |
|
| 2015 |
Mukherjee A, Ma Y, Yuan F, Gong Y, Fang Z, Mohamed EM, Berrios E, Shao H, Fang X. Lysophosphatidic Acid Up-Regulates Hexokinase II and Glycolysis to Promote Proliferation of Ovarian Cancer Cells. Neoplasia (New York, N.Y.). 17: 723-34. PMID 26476080 DOI: 10.1016/J.Neo.2015.09.003 |
0.506 |
|
| 2015 |
Nepomuceno AI, Shao H, Jing K, Ma Y, Petitte JN, Idowu MO, Muddiman DC, Fang X, Hawkridge AM. In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans. Analytical and Bioanalytical Chemistry. PMID 26159569 DOI: 10.1007/S00216-015-8862-4 |
0.381 |
|
| 2014 |
Jin L, Li C, Li R, Sun Z, Fang X, Li S. Corticotropin-releasing hormone receptors mediate apoptosis via cytosolic calcium-dependent phospholipase A₂ and migration in prostate cancer cell RM-1. Journal of Molecular Endocrinology. 52: 255-67. PMID 24776847 DOI: 10.1530/JME-13-0270 |
0.359 |
|
| 2013 |
Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Molecular Cancer Therapeutics. 12: 2640-50. PMID 24126433 DOI: 10.1158/1535-7163.Mct-13-0066 |
0.442 |
|
| 2013 |
Wu J, Mukherjee A, Lebman DA, Fang X. Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta Oncogene. 32: 3198-3206. PMID 22824789 DOI: 10.1038/Onc.2012.325 |
0.435 |
|
| 2013 |
Shao H, Jing K, Mahmoud E, Fang X, Yu C. Abstract 3290: Modulation of AKT, ERK and Mcl-1 by apigenin sensitizes colon cancer cells to anti-tumor activities of ABT263. Cancer Research. 73: 3290-3290. DOI: 10.1158/1538-7445.Am2013-3290 |
0.446 |
|
| 2012 |
Zhang Y, Arnatt CK, Zhang F, Wang J, Haney KM, Fang X. The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents. Bioorganic & Medicinal Chemistry Letters. 22: 5093-7. PMID 22770928 DOI: 10.1016/J.Bmcl.2012.05.127 |
0.413 |
|
| 2012 |
Mukherjee A, Wu J, Barbour S, Fang X. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. The Journal of Biological Chemistry. 287: 24990-5000. PMID 22665482 DOI: 10.1074/Jbc.M112.340083 |
0.507 |
|
| 2012 |
Van DN, Roberts CF, Marion JD, Lépine S, Harikumar KB, Schreiter J, Dumur CI, Fang X, Spiegel S, Bell JK. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 3188-98. PMID 22532440 DOI: 10.1096/Fj.11-202333 |
0.438 |
|
| 2011 |
Wu J, Mukherjee A, Lebman DA, Fang X. Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFβ. Molecular Cancer Research : McR. 9: 1562-70. PMID 21890597 DOI: 10.1158/1541-7786.Mcr-11-0340 |
0.47 |
|
| 2010 |
Li L, Lee PS, Yan C, Zhai T, Fang X, Liao M, Koide Y, Bando Y, Golberg D. Ultrahigh-performance solar-blind photodetectors based on individual single-crystalline In₂Ge₂O₇ nanobelts. Advanced Materials (Deerfield Beach, Fla.). 22: 5145-9. PMID 20859947 DOI: 10.1002/Adma.201002608 |
0.351 |
|
| 2010 |
Ramachandran S, Shida D, Nagahashi M, Fang X, Milstien S, Takabe K, Spiegel S. Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. Febs Letters. 584: 4077-82. PMID 20804754 DOI: 10.1016/J.Febslet.2010.08.035 |
0.498 |
|
| 2010 |
Song Y, Dilger E, Bell J, Barton WA, Fang X. Large scale purification and characterization of recombinant human autotaxin/lysophospholipase D from mammalian cells. Bmb Reports. 43: 541-6. PMID 20797316 DOI: 10.5483/Bmbrep.2010.43.8.541 |
0.32 |
|
| 2010 |
Oyesanya RA, Greenbaum S, Dang D, Lee Z, Mukherjee A, Wu J, Dent P, Fang X. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Molecular Cancer. 9: 8. PMID 20074357 DOI: 10.1186/1476-4598-9-8 |
0.699 |
|
| 2009 |
Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, ... Fang X, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 15: 539-50. PMID 19477432 DOI: 10.1016/J.Ccr.2009.03.027 |
0.425 |
|
| 2009 |
Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 492-501. PMID 19147754 DOI: 10.1158/1078-0432.Ccr-08-1945 |
0.703 |
|
| 2009 |
Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, Fulkerson Z, Fulerson Z, Berdyshev E, Natarajan V, Fang X, van Meeteren LA, Moolenaar WH, Mills GB, Morris AJ, et al. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. The Journal of Biological Chemistry. 284: 7385-94. PMID 19139100 DOI: 10.1074/Jbc.M807820200 |
0.307 |
|
| 2008 |
Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute. 100: 1630-42. PMID 19001604 DOI: 10.1093/Jnci/Djn378 |
0.51 |
|
| 2008 |
Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK, Fang X. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Molecular Biology of the Cell. 19: 5435-45. PMID 18843048 DOI: 10.1091/Mbc.E08-03-0316 |
0.453 |
|
| 2008 |
Shida D, Fang X, Kordula T, Takabe K, Lépine S, Alvarez SE, Milstien S, Spiegel S. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Research. 68: 6569-77. PMID 18701480 DOI: 10.1158/0008-5472.Can-08-0411 |
0.51 |
|
| 2008 |
Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB. Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. The Journal of Biological Chemistry. 283: 16818-29. PMID 18408217 DOI: 10.1074/jbc.M710177200 |
0.311 |
|
| 2008 |
Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB. Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 105: 5248-53. PMID 18367674 DOI: 10.1073/Pnas.0704242105 |
0.301 |
|
| 2008 |
Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, Dent P, Kordula T, Zhou H, Fang X. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 2639-51. PMID 18362203 DOI: 10.1096/Fj.07-101428 |
0.717 |
|
| 2007 |
Song Y, Wilkins P, Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J, Barbour SE, Fang X. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. The Biochemical Journal. 406: 427-36. PMID 17555408 DOI: 10.1042/Bj20070631 |
0.714 |
|
| 2006 |
Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Research. 66: 2740-8. PMID 16510595 DOI: 10.1158/0008-5472.Can-05-2947 |
0.529 |
|
| 2004 |
Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang X. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. The Journal of Biological Chemistry. 279: 51075-81. PMID 15466414 DOI: 10.1074/Jbc.M408607200 |
0.375 |
|
| 2004 |
Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. The Journal of Biological Chemistry. 279: 39541-54. PMID 15252041 DOI: 10.1074/Jbc.M403449200 |
0.348 |
|
| 2004 |
Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. The Journal of Biological Chemistry. 279: 9653-61. PMID 14670967 DOI: 10.1074/Jbc.M306662200 |
0.334 |
|
| 2003 |
Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Research. 63: 1073-82. PMID 12615725 |
0.391 |
|
| 2003 |
Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. The Journal of Biological Chemistry. 278: 11962-9. PMID 12554733 DOI: 10.1074/Jbc.M209168200 |
0.326 |
|
| 2002 |
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochimica Et Biophysica Acta. 1582: 257-64. PMID 12069836 DOI: 10.1016/S1388-1981(02)00179-8 |
0.415 |
|
| 2002 |
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treatment and Research. 107: 259-83. PMID 11775454 |
0.374 |
|
| 2000 |
Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. The Biochemical Journal. 352: 135-43. PMID 11062066 DOI: 10.1042/0264-6021:3520135 |
0.312 |
|
| 2000 |
Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Annals of the New York Academy of Sciences. 905: 188-208. PMID 10818454 DOI: 10.1111/j.1749-6632.2000.tb06550.x |
0.432 |
|
| Show low-probability matches. |